Features of Undiagnosed Breast Cancers at Screening Breast MR Imaging and Potential Utility of Computer-Aided Evaluation

Mirinae Seo, MD1,2, Nariya Cho, MD1,3,4, Min Sun Bae, MD1, Hye Ryoung Koo, MD1,5, Won Hwa Kim, MD1, Su Hyun Lee, MD1, Ajung Chu, MD1,6

1Department of Radiology, Seoul National University Hospital, Seoul 03080, Korea; 2Department of Radiology, Chung-Ang University Hospital, Seoul 06973, Korea; 3Department of Radiology, Seoul National College of Medicine, Seoul 03080, Korea; 4Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul 03080, Korea; 5Department of Radiology, Hanyang University College of Medicine, Seoul 04763, Korea; 6Department of Radiology, SMG-SNU Boramae Medical Center, Seoul 07061, Korea

**Objective:** To retrospectively evaluate the features of undiagnosed breast cancers on prior screening breast magnetic resonance (MR) images in patients who were subsequently diagnosed with breast cancer, as well as the potential utility of MR-computer-aided evaluation (CAE).

**Materials and Methods:** Between March 2004 and May 2013, of the 72 consecutive pairs of prior negative MR images and subsequent MR images with diagnosed cancers (median interval, 32.8 months; range, 5.4–104.6 months), 36 (50%) had visible findings (mean size, 1.0 cm; range, 0.3–5.2 cm). The visible findings were divided into either actionable or underthreshold groups by the blinded review by 5 radiologists. MR imaging features, reasons for missed cancer, and MR-CAE features according to actionability were evaluated.

**Results:** Of the 36 visible findings on prior MR images, 33.3% (12 of 36) of the lesions were determined to be actionable and 66.7% (24 of 36) were underthreshold; 85.7% (6 of 7) of masses and 31.6% (6 of 19) of non-mass enhancements were classified as actionable lesions. Mimicking physiologic enhancements (27.8%, 10 of 36) and small lesion size (27.8%, 10 of 36) were the most common reasons for missed cancer. Actionable findings tended to show more washout or plateau kinetic patterns on MR-CAE than underthreshold findings, as the 100% of actionable findings and 46.7% of underthreshold findings showed washout or plateau (p = 0.008).

**Conclusion:** MR-CAE has the potential for reducing the number of undiagnosed breast cancers on screening breast MR images, the majority of which are caused by mimicking physiologic enhancements or small lesion size.

**Index terms:** False negative breast cancer; Magnetic resonance imaging; Computer-aided evaluation

---

**INTRODUCTION**

Breast magnetic resonance (MR) imaging screening is currently recommended in addition to mammography for women with breast cancer antigen (BRCA) gene mutation or those with a lifetime risk (20–25% or greater) of...
search of our radiological database revealed that 9088 consecutive preoperative MR examinations between March 2004 and May 2013 and 2379 consecutive screening breast MR examinations in 1156 women between March 2008 and May 2013 were performed in our institution. Among them, 72 pairs of breast MR images of 72 patients, including both prior MR images without a diagnosis of cancer, as well as subsequent MR images that led to a cancer diagnosis, were found (median interval, 32.8 months; range, 5.4–104.6 months). Interval between prior and subsequent MR was ≤ 24 months in 28 cases, from 25–48 months in 24 cases, and ≥ 49 months in 20 cases. Thirty-eight % (28 of 72) of prior negatively reported breast MR images were from contralateral breast screening during preoperative MR examinations and 62% (44 of 72) were from screening examinations for high risk women. Two radiologists (with 15 years of experience and with 3 years of experience in interpreting breast MR images) reviewed the 72 pairs of MR images in consensus, with the information of medical records regarding image-guided needle localization, surgical procedure, and final surgical histopathology to determine whether the subsequently detected cancers were visible on prior MR images. Of the 72 areas of prior MR images where cancer later developed, 36 (50%) of prior MR images in 36 women (median age, 46 years; range, 28–67 years) had visible findings and they were finally included in the analysis (Table 1).

Histopathologic information was obtained from electronic medical records. Tumors were classified as estrogen receptor positive if > 10% of the cells were stained positively. The staining of c-erbB-2 was scored as 0, 1+, 2+, or 3+. Tumors with a 3+ score were classified as human epidermal growth receptor-2 (HER-2) positive, and tumors with a 0 or 1+ score were classified as negative. For tumors with a 2+ score, gene amplification using fluorescence in situ hybridization was performed and the ratios of HER-2 gene copies to the centromeric region of chromosome 17 ratios of ≥ 2.2 were interpreted as positive.

MR Imaging Technique and Interpretation in Clinical Practice

Between January 2004 and December 2006, MR examinations were performed using a 1.5T system (Sonata, Siemens Medical Systems, Erlangen, Germany) and a dedicated double-breast coil. DCE-MR images of the unilateral sagittal plane were obtained with 1 pre-contrast and 4 post-contrast series, using a T1-weighted three-
dimensional (3D) fast low-angle shot sequence with fat suppression in a sagittal plane (repetition time [TR]/echo time [TE], 4.9 ms/1.8 ms; matrix, 224 x 448; flip angle, 12°; field of view, 170 mm; section thickness, 1.0 mm; no gap). Between January 2007 and May 2013, the MR examinations were performed using a 1.5T system (Signa; General Electric Medical Systems, Milwaukee, WI, USA) and a dedicated phased-array breast coil (8-channel HD breast array, General Electric Medical Systems). Each examination included bilateral sagittal plane, fat-suppressed T2-weighted fast spin-echo images (TR/TE, variable from 5500 to 7150/82; matrix, 256 x 160; field of view, 200 x 200 mm; slice thickness, 1.5-mm; no gap), and DCE-MR images. The DCE-MR images were obtained with 1 pre-contrast and 5 post-contrast series, using a fat-suppressed T1-weighted 3D fast spoiled gradient echo sequence (TR/TE, 6.5 ms/2.5 ms; matrix, 256 x 160; flip angle, 10°; field of view, 200 x 200 mm; slice thickness, 1.5-mm; no gap). Gadobutrol (Gadovist, Bayer Healthcare, Berlin, Germany) at a dose of 0.1 mmol/kg was injected into an ante-cubital vein using an automated injector (Spectris MR, Medrad Europe, Maastricht, the Netherlands) at a rate of 2 mL/sec, followed by 20-mL of saline flush. The interval between the start of the contrast injection and the acquisition of the first post-contrast series was 15 seconds. The acquisition time of each post-contrast series was 76 seconds. Five post-contrast image series were obtained at 91, 180, 360, 449, and 598 seconds after the start of the contrast injection. For all of the MR examinations, early subtraction, axial reformatted images, and maximum intensity projection images were generated. The lesion kinetic features were visually assessed by the whole series of DCE-MR images and a region of interest (ROI) was manually placed for the plotting of signal intensity using a Picture Archiving and Communication System (PACS) workstation. MR-CAE was not routinely used for the initial clinical interpretation.

| Table 1. Clinicopathologic Features of 36 Women with Undiagnosed Breast Cancers with Visible Findings on Prior MR Images |
|---------------------------------------------------------------|
| Features                                                   | No. of Patients (n = 36) |
| Age at prior MR imaging                                    |                           |
| < 45 years                                                  | 17                        |
| ≥ 45 years                                                  | 19                        |
| Risk factor                                                |                           |
| Personal history of breast cancer                           | 32                        |
| BRCA mutation                                               | 4                         |
| Presentation of subsequent cancer                           |                           |
| Asymptomatic, found at imaging                             | 33                        |
| Clinical                                                   | 3                         |
| Interval between prior and subsequent MR examinations       |                           |
| ≤ 24 months                                                 | 20                        |
| 25–48 months                                                | 11                        |
| ≥ 49 months                                                 | 5                         |
| Histopathologic type and size of subsequent cancer (mean ± standard deviation)* |     |
| Invasive carcinoma (2.1 ± 2.0 cm)                          | 25                        |
| Ductal carcinoma in situ (2.1 ± 1.3 cm)                    | 11                        |
| Nuclear grade*                                              |                           |
| Low                                                        | 3                         |
| Intermediate                                               | 10                        |
| High                                                       | 23                        |
| Estrogen receptor status                                    |                           |
| Positive                                                   | 16                        |
| Negative                                                   | 20                        |
| HER-2 receptor status                                       |                           |
| Positive                                                   | 15                        |
| Negative                                                   | 21                        |

*Histopathologic features were determined using surgical specimens except for 1 patient who did not undergo curative surgery due to lung metastasis. HER-2 = human epidermal growth receptor 2
Blinded and Unblinded Review for Visible Findings on Prior MR Images

Five radiologists who had not originally interpreted the MR images participated as readers to classify the 36 visible findings on prior MR images as the actionable or the underthreshold group. The readers were fellowship-trained and had an average of 4.3 years of experience (range, 2–8 years) in interpreting MR examinations. All readers were blinded to the original MR reports, clinical and histopathological findings, as well as the proportions of benign and malignant cases. However, they were made aware of the image number and the location of the lesions because the purpose of this blinded review was not to evaluate detection ability but to determine the actionability of visible findings. Thirty-six prior MR images with malignant visible findings were randomly mixed with 65 control MR images with benign findings, which had been detected at the time of screening MR images and had been confirmed as benign histology using surgical excision or MR-guided vacuum-assisted biopsy. The benign lesions included fibrocystic change (n = 19), fibroadenoma (n = 16), intraductal papilloma (n = 14), florid ductal epithelial hyperplasia (n = 6), sclerosing adenosis (n = 4), nodular adenosis (n = 2), columnar cell change (n = 2), adenosis (n = 1), and ductectasia (n = 1). There was no difference in the mean lesion size between 65 benign lesions and 36 malignant lesions (1.17 ± 0.73 cm vs. 0.94 ± 0.80 cm, p = 0.170) on MRI. Non-mass enhancements were more frequently found in malignant lesions than benign lesions (52.7% [19/36] vs. 16.9% [11/65], p < 0.001). The readers were asked to classify the Breast Imaging Reporting and Data System (BI-RADS) final assessment category for the 101 lesions using the PACS workstation (16). The use of BI-RADS category 0 was discouraged. Of the 36 visible findings on prior MR images, lesions classified as BI-RADS category 4 or 5 by ≥ 3 of the 5 radiologists were determined to be actionable. Lesions classified as BI-RADS category 4 or 5 by ≤ 2 of the 5 radiologists were determined as underthreshold.

Additionally, 2 radiologists who did not participate in the blinded review analyzed the lesion size, imaging findings, and level of background parenchymal enhancement (BPE) according to the BI-RADS Atlas (16). Lesion size was defined as the largest diameter of the enhancing lesion on the early phase of DCE-MR images. The likely reasons for the undiagnosed cancers were classified as follows: 1) mimicking of physiologic enhancement, 2) mimicking of postoperative change, 3) multiple distracting lesions, 4) mismanagement, 5) mimicking of a lymph node, or 6) small lesion size (≤ 5 mm). When ≥ 2 reasons were involved in a case, the most influential reason was selected.

Computer-Aided Evaluation

A commercially available CAE program (CADSTREAM version 4.1.3, Confirma, Inc., Kirkland, WA, USA) was retrospectively applied to the prior MR images with visible findings. The CAE program incorporated the pre-contrast, the early first post-contrast (obtained 91 seconds after the contrast injection), and the last post-contrast (obtained 598 seconds after the contrast injection) T1-weighted images and subsequently calculated the pixel signal intensity. When an enhancing lesion increased the signal intensity by > 50% at the first post-contrast series, as compared to the pre-contrast series, it was coded as a color overlay map. The initial phase was classified as the slow (< 50% increase), medium (50–100%), or rapid (> 100% increase) enhancement, and the delayed phase was classified as persistent, plateau, or washout. Depending on the pixel signal intensity on the delayed post-contrast series compared to the first post-contrast series, the persistent type was defined as an increased signal intensity of ≥ 10%, displayed as blue. The plateau type defined as an increased signal intensity of < 10% and a decreased signal intensity of < 10%, was displayed as yellow. The washout type was defined as a decreased signal intensity of ≥ 10%, which was displayed as red. The most suspicious (washout > plateau > persistent) kinetic feature in an enhancing lesion was defined as its kinetic pattern, as previously suggested (14).

Statistical Analysis

The lesion size, MR imaging features, and CAE features between the actionable and underthreshold groups were compared using Student’s t test or Fisher’s exact test. SPSS version 19 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. Two-tailed p values of < 0.05 were considered to be statistically significant.

RESULTS

Of the 36 women, 32 women had personal histories of breast cancer and 4 women were carriers of BRCA mutation (Table 1). Thirty-three subsequent cancers (91.7%, 33 of 36) were detected during screening mammography (n = 4), screening US (n = 17), or screening MR examination.
(n = 12), and 3 cancers (8.3%, 3 of 36) were detected by palpable symptoms before the next scheduled screening round (interval cancers). Twenty-five cases (69.4%, 25 of 36) were invasive carcinomas, and the other 11 cases (30.6%, 11 of 36) were ductal carcinomas in situ. The median interval between prior and subsequent MR examinations was 17.7 months (range, 5.4–92.6 months).

Of the 36 visible findings, 33.3% (12 of 36) were determined to be actionable and 66.7% (24 of 36) were underthreshold findings (Table 2). The mean lesion size of actionable lesions was larger than that of underthreshold lesions (1.4 ± 1.2 cm vs. 0.7 ± 0.3 cm, p = 0.019). Minimal or mild BPE tended to be more frequently associated with the actionable lesions than moderate or marked BPE (75.0% [9 of 12] vs. 33.3% [8 of 24], p = 0.033). No focus lesions (0 of 10) were in the actionable group, whereas 85.7% (6 of 7) of masses and 31.6% (6 of 19) of non-mass enhancements were in the actionable group (p = 0.005). Mass descriptors of spiculated margin (n = 2), rim enhancement (n = 2), and non-mass enhancement descriptors of segmental distribution (n = 1), regional distribution (n = 1), and clustered ring enhancement (n = 1) were only found in the actionable group. The reasons for undiagnosed cancers commonly included mimicking physiologic enhancement (27.8%, 10 of 36) (Fig. 1), small lesion size (27.8%, 10 of 36), mimicking postoperative change (19.4%, 7 of 36), and

### Table 2. MR Imaging Features of Undiagnosed Breast Cancers with Visible Findings on Prior MR Images

| Features                          | Terms                  | Actionable Group (n = 12) | Underthreshold Group (n = 24) | P     |
|----------------------------------|------------------------|---------------------------|-------------------------------|-------|
| Lesion size (mean ± standard deviation)* | 1.4 ± 1.2 cm           | 0.7 ± 0.3 cm              | 0.019                         |
| Background parenchymal enhancement |                        |                           |                               | 0.033 |
| Minimal or mild                  | 9 (75)                 | 8 (33.3)                  |                               |
| Moderate or marked               | 3 (25)                 | 16 (66.7)                 |                               |
| Findings                         |                        |                           |                               | 0.005 |
| Focus                            | 0 (0)                  | 10 (41.7)                 |                               |
| Mass                             | 6 (50)                 | 1 (4.2)                   |                               |
| Shape                            | Oval                   | 2                         | 0                             |
|                                  | Irregular              | 4                         | 1                             |
| Margin                           | Smooth                 | 2                         | 0                             |
|                                  | Irregular              | 2                         | 1                             |
|                                  | Spiculated             | 2                         | 0                             |
| Enhancement                      | Homogeneous            | 2                         | 0                             |
|                                  | Heterogeneous          | 2                         | 1                             |
| Non-mass enhancement             | 6 (50)                 | 13 (54.2)                 |                               |
| Distribution                     | Focal                  | 3                         | 12                            |
|                                  | Linear                 | 1                         | 1                             |
|                                  | Segmental              | 1                         | 0                             |
|                                  | Regional               | 1                         | 0                             |
| Enhancement pattern              | Homogeneous            | 0                         | 1                             |
|                                  | Heterogeneous          | 4                         | 11                            |
|                                  | Clumped                | 1                         | 1                             |
|                                  | Clustered ring         | 1                         | 0                             |
| Reasons for missed cancer        |                        |                           |                               | 0.015 |
| Mismanagement                    | 2 (16.7)               | 0 (0)                     |                               |
| Multiple distracting lesions     | 3 (25.0)               | 3 (12.5)                  |                               |
| Mimicking postoperative change   | 2 (16.7)               | 5 (20.8)                  |                               |
| Mimicking lymph node             | 1 (8.3)                | 0 (0)                     |                               |
| Mimicking physiologic enhancement | 4 (33.3)               | 6 (25.0)                  |                               |
| Small lesion size                | 0 (0)                  | 10 (41.7)                 |                               |

Data are numbers of lesions. Values in parentheses are percentages calculated on basis of each group. *Lesion size was defined as largest diameter of enhancing lesion in early phase of dynamic contrast-enhanced MR images.
multiple distracting lesions (16.7%, 6 of 36) (Fig. 2).

MR-CAE was available for 25 prior MR images, which included 10 actionable and 15 underthreshold lesions (Table 3). At a 50% enhancement threshold level of CAE, 84% (21 of 25) of the lesions displayed color coding and 68% (17 of 25) of the lesions showed a washout or plateau component. All 4 lesions not displaying color coding at a 50% threshold level were underthreshold group and their lesion size ranged from 0.4 cm to 0.7 cm on MR images. The actionable findings tended to show more washout or plateau kinetic

---

**Fig. 1. Screening breast MR images of 31-year-old woman with personal history of contralateral breast cancer.**

Breast MRI was reported as negative finding with severe background parenchymal enhancement. This case was classified as actionable and reason for undiagnosis was determined as severe background parenchymal enhancement. Pre-contrast (A), early post-contrast (B), and delayed post-contrast (C) phase sagittal MR images show focal heterogeneous non-mass enhancement in upper breast (arrows). D. Retrospectively applied MR-computer-aided evaluation image shows lesion displaying mixed red, yellow, and blue color codings indicative of washout kinetic pattern based on most suspicious feature (arrows). E. Seven months later, patient was diagnosed with 1.6 cm high-grade invasive ductal carcinoma. Diagnostic MR image shows irregular, rim-enhancing mass (arrow).
patterns than the underthreshold findings, as the 100% (10 of 10) of actionable findings and 46.7% (7 of 15) of underthreshold findings showed washout or plateau kinetic patterns on MR-CAE ($p = 0.008$) (Figs. 1, 2). Five actionable masses were undiagnosed due to mismanagement ($n = 2$), multiple distracting lesions ($n = 2$), and mimicking physiologic enhancement ($n = 1$). Five actionable non-mass enhancement lesions were undiagnosed due to mimicking physiologic enhancement ($n = 2$), mimicking postoperative change ($n = 2$), and mimicking a lymph node ($n = 1$).

**DISCUSSION**

Our review of prior negative screening breast MR images

---

**Fig. 2. Screening breast MR images of 46-year-old woman with personal history of contralateral breast cancer.**

Breast MRI was reported as multiple benign findings in both breasts. This case was classified as actionable and reason for missed cancer was determined as multiple distracting lesions. **A.** Three-dimensional maximum intensity projection image of early post-contrast phase, sagittal MR images show multiple enhancing foci and masses in breast (arrow). **B.** Retrospectively applied MR-computer-aided evaluation image shows lesion displaying mixed red, yellow, and blue color codings indicative of washout kinetic patterns based on most suspicious feature (arrow). **C.** Seven months later, she was diagnosed with 1.0 cm intermediate grade invasive ductal carcinoma. Diagnostic MR image shows irregular, heterogeneously enhancing mass (arrow).

**Table 3. MR-CAE Features of Undiagnosed Breast Cancers with Visible Findings on Prior MR Images**

| Features                        | Actionable Group (n = 10) | Underthreshold Group (n = 15) | $P$  |
|---------------------------------|---------------------------|------------------------------|------|
| Enhancement at 50% threshold    |                           |                              | 0.26 |
| Absence                         | 0 (0)                     | 4 (26.7)                     |      |
| Presence                        | 10 (100)                  | 11 (73.3)                    |      |
| Delayed enhancement             |                           |                              |      |
| Persistent                      | 0                         | 4                             |      |
| Plateau                         | 2                         | 1                             |      |
| Washout                         | 8                         | 6                             |      |
| Combined CAE features           |                           |                              | 0.008|
| No enhancement, persistent pattern| 0 (0)                    | 8 (53.3)                     |      |
| Focus                           | 0                         | 4                             |      |
| Non-mass enhancement            | 0                         | 4                             |      |
| Plateau or washout pattern      | 10 (100)                  | 7 (46.7)                     |      |
| Focus                           | 0                         | 1                             |      |
| Mass                            | 5                         | 1                             |      |
| Non-mass enhancement            | 5                         | 5                             |      |

Data are numbers of lesions. Values in parentheses are percentages calculated on basis of each group. CAE = computer-aided evaluation
in subsequently diagnosed breast cancer patients showed that 27.8% (10 of 36) of the lesions were not diagnosed because of mimicking physiologic enhancements, 27.8% (10 of 36) of the lesions were not diagnosed because of small lesion size, and actionable findings tended to show more washout or plateau kinetic patterns on MR-CAE than underthreshold findings (100% vs. 46.7%, \( p = 0.008 \)). Our results were consistent with those of previous studies in which small lesion size, extensive BPE, benign appearance, or mimicking post-operative scars were common reasons for false-negative diagnoses, although there were evident enhancing findings on prior MR images (9, 10).

Our study differed from these previous studies in the analyses of findings on prior MR images for actionability. Understanding the features of actionable findings that were prospectively overlooked can help radiologists reduce the false-negative diagnoses of screening MR images in real clinical practice. With regard to the actionable group, the mass lesion (85.7%, 6 of 7) was observed more frequently than the non-mass enhancement (31.6%, 6 of 19) or focus type (0%, 0 of 10) lesions (\( p = 0.005 \)). Notably, spiculated margin (\( n = 2 \)), rim enhancement (\( n = 2 \)), segmental distribution (\( n = 1 \)), regional distribution (\( n = 1 \)), or clustered ring enhancement (\( n = 1 \)) noted in the actionable group were previously well-known terms for suspicious findings with high positive predictive values (17). The reason for lack of prospective detection of actionable findings despite presentation with previously well-known suspicious findings, may be attributed to the insufficient conspicuity of the lesion or the subtle differences in the signal intensity of lesions from the adjacent background parenchyma. Indeed, the primary reasons for the undiagnosed actionable findings in our study were mimicking physiologic enhancements (33.3%, 4 of 12) or multiple distracting lesions (25.0%, 3 of 12). Increased mammographic density is associated with decreased diagnostic accuracy of breast cancer detection; likewise, greater BPE may limit MR imaging interpretation. Despite no difference in the cancer yield, sensitivity or specificity between the greater and less BPE groups (18), recent studies reported that moderate or marked BPE led to more abnormal interpretations or biopsies (18, 19), which indicated reduced reader confidence. In our study, moderate or marked BPE tended to be more frequently associated with underthreshold lesions than minimal or mild BPE. Thus, the role of MR-CAE for the detection of suspicious kinetic features from the adjacent background parenchyma may be promising.

In our study, we found that 84% (21 of 25) of enhancing lesions displayed color coding and actionable findings tended to show more washout or plateau kinetic patterns than underthreshold findings. Although a recent multi-institutional study reported that the addition of MR-CAE did not achieve a statistically significant improvement in overall accuracy in the interpretation of MR images (20), MR-CAE reportedly improves the detection of the delayed washout component for the entire tumor pixels (21). Moreover, the washout kinetic pattern on DCE-MR image was not the only significantly different MR-CAE feature between the benign and malignant lesions in a study by Wang et al. (14); it was also correlated with a high histologic grade, high Ki-67 expression and increased vascular permeability (22, 23). The visual assessment or manual placement of ROIs for kinetic feature measurement in daily practice has a limitation in the discrimination of subtle suspicious features for entire tumors. Thus, when a washout or plateau component is displayed on an enhancing lesion, careful attention is required to rule out the likelihood of early cancer.

With regard to the lesion type and MR-CAE, controversy remains whether MR-CAE is helpful for the non-mass enhancements, as well as mass lesions, although some studies have reported that MR-CAE is helpful in differentiation of benign and malignant non-mass enhancements, as well as mass lesions (21, 24). In our study, 5 actionable non-mass enhancement lesions were undiagnosed due to mimicking physiologic enhancement (\( n = 2 \)), mimicking postoperative change (\( n = 2 \)), and mimicking a lymph node (\( n = 1 \)). We believe that MR-CAE has potential to reduce false negative diagnosis for non-mass enhancement lesions that were misperceived as physiologic enhancement or postoperative change.

In the underthreshold group, 10 foci, 1 mass, and 13 non-mass enhancement lesions had a mean lesion size smaller than that of the actionable group (0.7 ± 0.3 cm vs. 1.4 ± 1.2 cm, \( p = 0.019 \)). It is generally suggested that malignant foci < 5 mm can be missed on MR images because of insufficient angiogenesis or partial volume effects, which might be inevitable (10, 25). Undiagnosed cancers due to mimicking postoperative change, was similar to the earlier study in which the previous lumpectomy was one of the primary causes of misinterpretation of a malignant enhancement (10). Although MR imaging is believed to be helpful in distinguishing scar from a recurrent tumor (26,
27), 71.4% (5 of 7) of the lesions mimicking postoperative change in our study were underthreshold.

Our study had several limitations. First, the sample size was possibly too small to draw a solid conclusion. Second, we used 1 commercially available MR-CAE program. Various types of MR-CAE program, threshold level of kinetic feature assessment, and MR protocols could have affected the results. Third, we included malignant cases, which were missed at prior MRI and benign cases, which were biopsied due to a suspicious feature at MRI. Thus, our results cannot be generalized to all lesions considered for biopsy decision in clinical practice. Fourth, 13.9% of our study population showed ≥ 49 month interval between prior and subsequent MR examinations. Thus, although experienced radiologists confirmed their correspondence on both images, there might be a possibility of mismatched cases between prior and subsequent images. Fifth, our observation of more frequent washout or plateau components of enhancements on prior MR images in the actionable group do not directly translate to decreased false negative diagnoses; this is because cancers that show washout or plateau components on MR-CAE might be obscured by BPE containing multiple enhancing foci with plateau or washout components.

Moreover, if radiologists interpret all lesions with washout enhancing foci with plateau or washout components, it will also lead to increased false positive rate.

In conclusion, MR-CAE has the potential for reducing actionable, overlooked findings because more plateau or washout delayed enhancement patterns were found for actionable findings than for underthreshold findings, which can improve lesion conspicuity in cases showing greater BPE or multiple distracting lesions.

REFERENCES

1. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89

2. Krieger M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-437

3. Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance at high familial risk for breast cancer. J Clin Oncol 2005;23:8469-8476

4. Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004;292:1317-1325

5. Sardanelli F, Podo F, D’Agno1o G, Verdech1ia A, Santaquilani M, Musumeci R, et al. Multicenter comparative multimodality surveillance of women at genetic-familial high risk for breast cancer (HIBCRIT study): interim results. Radiology 2007;242:698-715

6. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005;365:1769-1778

7. Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, et al. MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007;370:485-492

8. Baur A, Bahrs SD, Speck S, Wietek BM, Krämer B, Vogel U, et al. Breast MRI of pure ductal carcinoma in situ: sensitivity of diagnosis and influence of lesion characteristics. Eur J Radiol 2013;82:1731-1737

9. Obdeijn IM, Loo CE, Rijnsburger AJ, Wasser MN, Bergers E, Kok T, et al. Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition. Breast Cancer Res Treat 2010;119:399-407

10. Pages EB, Millet I, Hoa D, Doyon FC, Taourel P. Undiagnosed breast cancer at MR imaging: analysis of causes. Radiology 2012;264:40-50

11. Birdwell RL, Ikeda DM, O’Shaughnessy KF, Sickles EA. Mammographic characteristics of 115 missed cancers later detected with screening mammography and the potential utility of computer-aided detection. Radiology 2001;219:192-202

12. Ikeda DM, Birdwell RL, O’Shaughnessy KF, Sickles EA, Brenner RJ. Computer-aided detection output on 172 subtle findings on normal mammograms previously obtained in women with breast cancer detected at follow-up screening mammography. Radiology 2004;230:811-819

13. Williams TC, DeMartini WB, Partridge SC, Peacock S, Lehman CD. Breast MR imaging: computer-aided evaluation program for discriminating benign from malignant lesions. Radiology 2007;244:94-103

14. Wang LC, DeMartini WB, Partridge SC, Peacock S, Lehman CD. MRI-detected suspicious breast lesions: predictive values of kinetic features measured by computer-aided evaluation. AJR Am J Roentgenol 2009;193:826-831

15. Yamaguchi K, Schacht D, Newsstead GM, Bradbury AR, Verp MS, Olopade OI, et al. Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases. AJR Am J Roentgenol 2013;201:1155-1163

16. Morris EA, Comstock CE, Lee CH. ACR BI-RADS® Magnetic Resonance Imaging. In: ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology.
17. Mahoney MC, Gatsonis C, Hanna L, DeMartini WB, Lehman C. Positive predictive value of BI-RADS MR imaging. Radiology 2012;264:51-58
18. DeMartini WB, Liu F, Peacock S, Eby PR, Gutierrez RL, Lehman CD. Background parenchymal enhancement on breast MRI: impact on diagnostic performance. AJR Am J Roentgenol 2012;198:W373-W380
19. Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA. Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up. AJR Am J Roentgenol 2011;196:218-224
20. Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD. Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers. AJR Am J Roentgenol 2013;200:W683-W689
21. Cho N, Kim SM, Park JS, Jang M, Kim SY, Chang JM, et al. Contralateral lesions detected by preoperative MRI in patients with recently diagnosed breast cancer: application of MR CAD in differentiation of benign and malignant lesions. Eur J Radiol 2012;81:1520-1526
22. Su MY, Cheung YC, Freehauf JP, Yu H, Nalcioglu O, Mechetner E, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 2003;18:467-477
23. Lee SH, Cho N, Kim SJ, Cha JH, Cho KS, Ko ES, et al. Correlation between high resolution dynamic MR features and prognostic factors in breast cancer. Korean J Radiol 2008;9:10-18
24. Liu YH, Xu L, Liu LH, Liu XS, Hou ZY, Hou DL, et al. 3.0T MR-CAD: Clinical Value in Diagnosis of Breast Tumor Compared with Conventional MRI. J Cancer 2014;5:585-589
25. Teifke A, Hlawatsch A, Beier T, Werner Vomweg T, Schadmand S, Schmidt M, et al. Undetected malignancies of the breast: dynamic contrast-enhanced MR imaging at 1.0 T. Radiology 2002;224:881-888
26. Soderstrom CE, Harms SE, Farrell RS Jr, Pruneda JM, Flamig DP. Detection with MR imaging of residual tumor in the breast soon after surgery. AJR Am J Roentgenol 1997;168:485-488
27. Belli P, Costantini M, Romani M, Marano P, Pastore G. Magnetic resonance imaging in breast cancer recurrence. Breast Cancer Res Treat 2002;73:223-235